Medeor’s cell therapy boosts immune tolerance in registrational trial of donor kidney recipients
Medeor Therapeutics’ Phase III single-dose cell therapy has seen more than half of a specific group of donor kidney recipients stop immunosuppression therapy for two years, sparking plans for an FDA filing.
Medeor’s MDR-101 is designed to induce and maintain a state known as mixed chimerism, which occurs when a low level of donor blood cells remains in the blood of a donor kidney recipient. MDR-101 treatment involves injecting blood stem cells and T cells from the donor into the receiving patient.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.